Checklist for Renflexis (infliximab-abda) Referral

Required documentation for all initial referrals

Patient	t	DOB	Date	New Start Maintenance		
Please	return completed checklist and	I checklist items for an ir	fusion referral:			
	Patient demographics (e.g. address, phone number, SSN, etc.)					
	Insurance information and copy of insurance card(s). Please indicate the insurance that is primary, and the insurance that is secondary, if applicable, and the subscriber's date of birth. o If insurance requires prior authorization, please provide the phone number and allow up to 15-30 days for this to be completed by one of our Infusion Coordinators.					
	Signed and completed Renflexis o Standard Order forms a	Standard Order (our order standard Order (our order standard order)	•			
	Supporting clinical MD notes to contraindications to convention		•			
	Required HepatAntibody, or HeLab results with	reening results: PPD (with	ear) : Hepatitis B Sur esults	FERON Gold Test <i>(within 3 years)</i> face Antigen, Hepatitis B Surface		
	Please indicate name and direct any additional information: o Name: o Phone Number:		act within your offic	e that we can speak with to obtain		
F	Paperwork can be faxed or em	nailed to (843)-824-232	7, <u>infusionemail@</u>	Particularishealthcare.com		
	Infusion Coordinators Bre	enna, Sadie or Stephai (843)-572-8	•	with any questions at		
	<u>Lor</u> Please mark preferred location and	w Country Rheumatology we will do our best to accor		e cannot make any guarantees.		
	200	Summervil 11 2nd Ave, Suite 201, Sun				
	116	Mount Pleas 5 Chuck Dawley Blvd, Mt.				
	2291	West Ashle Henry Tecklenburg Drive,	•	14		
documo informa review	ation is required. The patient wil	ce company for eligibility. I have an annual 30-minu	Our Infusion Coord te consult with our	d submit all required clinical linators will notify you if any further NP to obtain H&P for chart. We will y assistance as required. Thank you		
Low	Country Rheumatology Use Only	Existing Patient Yes N	o Physiciai	1		

Standard Orders for Renflexis (infliximab-abda) Administration

Patient	DOB	Dat	:e	
*NOTE: Patient is ineligible to receive Renfle				
infectious process due to the possibility of d	eveloping a super infectio	n related to its effe	ct on the immune system.	
Indication: Please indicate the highest level	of specificity.			
☐ K50.0 Crohn's Disease (small				
intestine)	Unspecified			
□ K50.1Crohn's Disease (large		Ulcerative	□ Other ICD-10 Code	
intestine)	(chronic) Colitis			
☐ K50.8 Crohn's Disease (small and	□ K51.8 Other Ulc	erative (chronic)		
large intestine)	Colitis			
☐ K63.2 Fistula of intestine	□ K51.0Universal	Ulcerative		
History:	(chronic) Pancolitis			
☐ Inadequate response to DMARDS		□ Unable to tolera	ITE DMARDS	
□ Rapid 3			Swollen/tender joints	
□ ESR/CRP	·			
	□ Progressive erosive arthropathy			
☐ HBsAg, HBsAb, HB core Ab, and HCAb	□ Recent or upcoming surgical procedure			
☐ History of skin cancer				
 concerns as noted on Infusion Reco Baseline vitals will be obtained prio be obtained more frequently if pati Titrate infusion over 2 hours as reco to previous infusion reaction. After 	, HCAb negative as, prior or upcoming surgerd or to administration, hourlent's condition warrants in the second of the second	y during infusion ant. ion guide for doses ver 1 hour as tolerat e infusion reaction as and follow-up app	protocol per Articularis Healthcare Policy	
Premedicate:	_ WCCK3			
□ No pre-med				
□ Pre-medicate x 1 dose 30 minutes prior to	each infusion with:			
•		□ 125mg Solu-Me	drol IV 🗆 Other	
-	25mg bendaryn 10/14	123mg 30m Wic	aroniv a other	
Additional orders/comments:				
Practice Name:		NPI:		
Physician Name:		State License:		
Physician Signature:	DEA #:			
Date:		UPIN:		